The overall aim of SCAPIS is to improve prediction and prevention of cardiovascular and
lung disease in the general population by identifying novel risk markers. This is also
the purpose of SCAPIS 2, which further aims to gain important insights into risk factors
and longitudinal development of heart, vascular and lung diseases such as atherosclerosis
and chronic obstructive pulmonary disease. SCAPIS 2 will investigate 15,000 study
participants approximately 8-10 years after the baseline examination SCAPIS 1.
The five overall objectives of SCAPIS 2 are:
To determine characteristics related to the natural progression of atherosclerosis
over 8-10 years.
To evaluate characteristics related to pathological cardiovascular aging over 8-10
years.
To determine characteristics related to the natural progression of lung function
over 8-10 years.
To determine risk factors associated with the progression of coronary
atherosclerosis and the development of impaired lung function or structural changes
of the lungs.
To compare outcome in individuals who are invited to SCAPIS 2 and those not invited.
SCAPIS 2 will recruit approximately 15,000 subjects randomly selected from the baseline
examination (SCAPIS 1) study population approximately 8-10 years after their initial
participation. During the SCAPIS 1 random samples of men and women aged 50-64 years were
drawn from each recruitment area in the Swedish population registry until approximately
30 000 subjects were included. The final number was 30 154 subjects with an even sex and
age distribution. The original recruitment process ensured that the study population in
SCAPIS 1 was representative for the Swedish population in general.
An invitation letter with brief information about SCAPIS 2 will be sent to randomly
selected individuals by mail, including phone number and e-mail address to the study
center. The invitation letter will refer to a study webpage where the subjects can
indicate if they are interested in participating in SCAPIS 2 and read the subject
information in advance (voluntary). The invitation also includes contact information to
the study center to be used if the subject prefers to not use the web page or has
questions. Subjects that have moved since their participation in SCAPIS 1 will be invited
to the same study center as their baseline examination.
The examinations will be performed during 2-3 days within approximately 2 weeks. Whenever
possible, all visits should be performed within a period of 4 weeks. Examinations that
are common for all sites include:
Medical history
Anthropometry
Clinical chemistry/hematology: Hb, p-Glucose, HbA1c, s-TG, s- Cholesterol, LDL, HDL,
creatinine, detailed leukocyte count)
Biobank sampling (plasma, serum, whole blood, and urine)
Spirometry
CO uptake
Questionnaires
Accelerometry (hip)
Electrocardiogram (ECG)
Heart rate
Blood pressure
Computed tomography (CT)
All subjects will be fasting overnight (at least 8 hours) before the first visit. If a
subject has not been fasting overnight, blood sampling should be rescheduled and
performed preferably at an extra visit but no later than Visit 2. For subjects with
elevated plasma glucose levels, an overnight fasting glucose measurement will be
repeated.
Subjects should be instructed to take their regular medication as usual also when
fasting. The only medication that should not be taken is medication for diabetes, per
oral as well as injections. Subjects with diabetes should be fasting as all other
subjects and should bring their medication to take when having breakfast at the clinic.
To obtain standardized conditions for the CT examination, subjects are recommended to be
fasting for at least 4 hours before intake of a standardized meal. The standardized meal
should be consumed 2 hours before the CT scan.
All clinical findings and assessment of risk should be taken care of according to current
guidelines and SCAPIS manual.